Compare CCEL & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | TELA |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 31.4M |
| IPO Year | 2022 | 2019 |
| Metric | CCEL | TELA |
|---|---|---|
| Price | $4.51 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 9.9K | ★ 139.6K |
| Earning Date | 10-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ 0.23 | N/A |
| Revenue | $25,384,279.00 | ★ $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | 9.76 | ★ 15.84 |
| 52 Week Low | $2.72 | $0.50 |
| 52 Week High | $4.90 | $1.51 |
| Indicator | CCEL | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 43.13 |
| Support Level | $3.19 | $0.61 |
| Resistance Level | $4.76 | $0.97 |
| Average True Range (ATR) | 0.46 | 0.12 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 70.41 | 11.57 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.